FindTrial
Sign In

Clinical study of Yiqi Tongluo Xiezhuo recipe in the treatment of chronic Renal failure (Qi deficiency and Blood stasis and damp-Heat Syndrome)

A single-center, randomized, parallel, positive control and open clinical trial of Yiqi Tongluo Xiezhuo recipe was carried out in 18-75-year-old patients with CKD stage III-IV (syndrome of qi&

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006776
Enrollment
Unknown
Registered
2022-11-14
Start date
2022-11-14
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

Control group:Niaoduqing granule is given in the basic treatment of western medicine.
Intervention group:Yiqi Tongluo Xiezhuo prescription is given in the basic treatment of western medicine.

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) meet the diagnostic criteria of CKD III-V in the 2012 KIDIGO guidelines, and effectively control the reversible factors that may lead to the aggravation or progression of the disease, such as infection, electrolyte disturbance, hypertension, hyperglycemia, etc.; (2) meet the diagnostic criteria of TCM syndrome of qi deficiency and blood stasis and damp-heat syndrome; (3) 18-75 years old; (4) voluntary subjects who understand and sign the informed consent form

Exclusion criteria

Exclusion criteria: (1) secondary chronic renal insufficiency caused by systemic lupus erythematosus; (2) patients who have received or are undergoing dialysis; renal transplant patients (3) with severe primary diseases of the heart, liver, brain, blood and other organs or systems, or with consumptive diseases such as tumors, hyperthyroidism, severe inflammation, etc. (4) those who have participated in clinical trials within 3 months or have used glucocorticoids, immunosuppressive drugs, Tripterygium wilfordii preparations, or are receiving the above treatment; (5) 24-hour urinary protein = 3.0g; serum albumin = 25g / L; (6) pregnant or lactating women: (7) those who are known to be allergic to drug ingredients; (8) the range of GFR fluctuation = 30% in the first 3 months of the group.

Design outcomes

Primary

MeasureTime frame
Glomerular filtration rate;—

Secondary

MeasureTime frame
Serum albumin;Hemoglobin;Blood urea nitrogen;Four items of blood lipid;TCM syndrome integral;Serum creatinine;Urinary protein / creatinine ratio;24-hour urinary protein quantification;—

Countries

China

Contacts

Public ContactLiu Weijing
liuweijing-1977@hotmail.com13010419760

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026